Trevi Therapeutics Inc. Company Profile
NASDAQ: TRVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 3:17 PM ET
Trevi Therapeutics at a glance
Trevi Therapeutics Inc. (NASDAQ: TRVI) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in New Haven, CT. Trevi Therapeutics is led by Ms. Jennifer L. Good and employs about 34 people. The company's shares have traded publicly since 2019.
At a market capitalization of $1.88 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001563880, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Trevi Therapeutics do?
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Business description based on the company's public filings.
Company information
- Legal name
- Trevi Therapeutics Inc.
- Ticker
- NASDAQ: TRVI
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Jennifer L. Good
- Employees
- 34
- Headquarters
- 195 Church Street, New Haven, CT, United States
- Phone
- 203 304 2499
- Website
- trevitherapeutics.com
- IPO year
- 2019
- Market cap
- $1.88B
- SEC CIK
- 0001563880
- Latest annual report
- 10-K · Mar 17, 2026
Companies similar to Trevi Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| XERSXeris Biopharma Holdings Inc. | 10.28 | +1.68% | $1.87B | vs TRVI |
| ADRXADARx Pharmaceuticals Inc. | 17.69 | +2.05% | $1.89B | vs TRVI |
| PVLAPalvella Therapeutics Inc. | 131.16 | +0.44% | $1.89B | vs TRVI |
| SRPTSarepta Therapeutics Inc. | 18.04 | +3.06% | $1.90B | vs TRVI |
| URGNUroGen Pharma Ltd. | 37.79 | -7.15% | $1.85B | vs TRVI |
| AGIOAgios Pharmaceuticals Inc. | 32.16 | +1.16% | $1.92B | vs TRVI |
| GPCRStructure Therapeutics Inc. ADR | 25.64 | -3.90% | $1.83B | vs TRVI |
| ZYMEZymeworks Inc. | 25.38 | -4.33% | $1.82B | vs TRVI |